Samsung Biologics to Participate in 2025 BIO International Convention

World's Largest Expo Draws 20,000 Visitors
Solo Booth for 13 Consecutive Years Since Founding

A bird's-eye view of Samsung Biologics' booth at the 2025 BIO International Convention. Photo by Samsung Biologics

On June 9, Samsung Biologics announced that it will participate in the 2025 BIO International Convention (BIO USA), the world's largest bio-pharmaceutical exhibition.

The BIO International Convention is organized annually by the Biotechnology Innovation Organization (BIO) and rotates among major bio-clusters in the United States every June. It is recognized as a key networking event where bio-pharmaceutical industry professionals from around the world gather to discuss partnerships.

This year's event will be held from June 16 to 19 (local time) at the Boston Convention & Exhibition Center in Massachusetts, under the theme "The World Can't Wait." More than 20,000 industry professionals from around the world are expected to attend.

Since its founding in 2011, Samsung Biologics has been the only Korean company to independently operate a booth for 13 consecutive years, demonstrating its strong global competitiveness in securing orders. For this year's event as well, the company will set up a 167-square-meter booth at the main entrance of the exhibition hall, the area with the highest foot traffic, to capture the attention of participants. In particular, to showcase its continuously expanding contract development and manufacturing organization (CDMO) capabilities, as well as new facilities and services, the company will install advanced exhibition features such as an LED wall and interactive touch screens to deliver a wide range of content in an engaging manner. By emphasizing the use of digital technologies, which have recently become a major topic in the bio-pharmaceutical industry, Samsung Biologics aims to enhance its image as an innovative brand for the future.

At the booth, the company will highlight its world-class biopharmaceutical production capacity of 784,000 liters, centered around its recently operational fifth plant. It will also showcase its ability to rapidly respond to new customer demands with multi-specific antibody development and production capabilities, as well as its newly launched antibody-drug conjugate (ADC) services this year. In addition, Samsung Biologics will present its expanded CDMO portfolio and digital transformation (DT) initiatives, including AI-based operations. By presenting these recent developments and its vision for becoming a global top-tier CDMO, the company aims to demonstrate its competitiveness and actively pursue collaborations across various fields.

Furthermore, Samsung Biologics plans to increase its brand recognition and market share in the U.S. and other global CDMO markets by placing exclusive promotional banners at key locations throughout the exhibition hall, such as the skybridge visible from the entrance and the stairs leading to the main event area. Through these diverse content initiatives, the company aims to expand contact points not only with existing global clients but also with new customers.

This content was produced with the assistance of AI translation services.